BioXcel Therapeutics (BTAI) Profit After Tax (2017 - 2026)

BioXcel Therapeutics has reported Profit After Tax for 10 years, with the latest figure at -$14.7 million in Q2 2026.

• On a quarterly basis, Profit After Tax rose 23.32% year-over-year to -$14.7 million in Q2 2026; TTM through Jun 2026 was -$70.9 million, a 39.08% decrease from a year earlier, with the FY2025 full-year figure at -$69.9 million, down 17.28% from the prior year.
• Profit After Tax was -$14.7 million for Q2 2026 at BioXcel Therapeutics, down from -$12.7 million in the prior quarter.
• The five-year high for Profit After Tax was -$7.3 million in Q1 2025, with the low at -$54.8 million in Q4 2022.
• Average Profit After Tax over 5 years is -$27.9 million, with a median of -$24.5 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 84.49% in 2024, then slumped 131.2% in 2025.
• Over 5 years, Profit After Tax stood at -$54.8 million in 2022, then jumped by 59.39% to -$22.3 million in 2023, then soared by 51.21% to -$10.9 million in 2024, then declined by 15.53% to -$12.5 million in 2025, then dropped by 17.28% to -$14.7 million in 2026.
• The last three Profit After Tax figures came in at -$14.7 million (Q2 2026), -$12.7 million (Q1 2026), and -$12.5 million (Q4 2025), per Business Quant data.